Clinical Research
Retina Associates of Utah is proud to partner with a variety of pharmaceutical companies to bring patients the newest innovations in retinal disease treatment. Currently, we are conducting nine (9) clinical studies with others in our research pipeline. From providing important safety and efficacy data for FDA approved Lucentis (monospecific anti-VEGF antibody), Susvimo (port delivery system aka implant) and Vabysmo (the first bispecific antiVEGF antibody) to safely administering other novel therapies including gene therapy, RAU strives to serve patients in Utah with innovative treatments for wet and dry macular degeneration, diabetic macular edema, retinal vein occlusions, and more.
To learn more details about our clinical studies or to inquire about how to participate, please contact our research department (801) 312-2070.
Current Clinical Studies
Currently Enrolling
A Phase 3 randomized, controlled, assessor masked trial comparing a single course and two repeat courses of treatment with AU-011 to 125I brachytherapy in subjects with small to medium choroidal melanoma (CM).
Port Delivery System with Lucentis (Susvimo) for Wet Macular Degeneration.
Randomized, Placebo-Controlled Study of Subcutaneous Pozelimab + Cemdisiran combination therapy or cemdisiran monotherapy for the Treatment of Geographic Atrophy.
Placebo-Controlled, multicenter, masked study to evaluate the efficacy, safety, tolerability, and Pharmacodynamics of multidose APL-3007 in combination with Syfovre/Pegcetacoplan (APL-2) in patients diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Closed Enrollment (In Active Follow Up)
Intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy
Intravitreal BI 771716 against pegcetacoplan in participants with geographic atrophy secondary to age-related macular degeneration.
Phase2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema.
Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema.
Parallel-Group study of EYP-1901, A Tyrosine Kinase Inhibitor (TKI), compared to Aflibercept in subjects with WET AMD.
Port Delivery System) Study to investigate the safety, tolerability, and pharmacokinetics of RO7250284 in patients with nAMD.
Intravitreal injections of RO7446603 alone and co-administered with Aflibercept in patients with Diabetic Macular Edema.
Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration.
Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration.
Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.
RGX-314 Gene Therapy in Participants with nAMD.
Studies in Our Pipeline
A Phase 3 study comparing the efficacy of EYP-1901 Against Aflibercept in DME